Inhibitor of apoptosis

Inhibitor of Apoptosis (IAP) Antagonist Drug Pipeline Market Insights Report 2022 Featuring Merck & Co., Novartis, Astex Pharmaceuticals, Ascentage Pharma, & Chia Tai Tianqing Pharmaceutical - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 16, 2022
Health, General Health, IAP, Antagonist, Clinical trial, Neoplasm, Cell death, III, Route, News, T-cell lymphoma, Route of administration, IAPS, Merck & Co., Discovery, II, NDA, XIAP, Acquisition, Inhibitor of apoptosis, Administration, Therapy, Astex, CRT, Head, Patient, Pharmaceutical industry, Vaccine, Merck, Apoptosis

This "Inhibitor Of Apoptosis (IAP) Antagonist- Pipeline Insight, 2022" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Inhibitor Of Apoptosis (IAP) Antagonist pipeline landscape.

Key Points: 
  • This "Inhibitor Of Apoptosis (IAP) Antagonist- Pipeline Insight, 2022" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Inhibitor Of Apoptosis (IAP) Antagonist pipeline landscape.
  • The assessment part of the report embraces, in depth Inhibitor of Apoptosis (IAP) Antagonist commercial assessment and clinical assessment of the pipeline products under development.
  • The companies which have their Inhibitor of Apoptosis (IAP) Antagonist drug candidates in the most advanced stage, i.e.
  • phase III include, Merck & Co.
    Inhibitor of Apoptosis (IAP) Antagonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Astex Pharmaceuticals Announces That Tolinapant (ASTX660), a Novel Antagonist of Cellular and X-linked Inhibitors of Apoptosis Proteins, Has Been Granted Orphan Drug Designation for the Treatment of T-cell Lymphomas by the US FDA

Retrieved on: 
Monday, August 31, 2020
Oncology, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Biology, Programmed cell death, Cell signaling, Proteins, Pharmaceuticals policy, Cell biology, Inhibitor of apoptosis, Orphan drug, Cellular Inhibitor of Apoptosis Protein 1, Apoptosis, XIAP, Tolinapant (ASTX660), T-Cell Lymphomas, Astex Pharmaceuticals, Inc.

Orphan drug designation is granted to drugs intended to treat a rare disease or condition.

Key Points: 
  • Orphan drug designation is granted to drugs intended to treat a rare disease or condition.
  • The designation provides for seven years of marketing exclusivity in the US following product approval, as well as certain tax incentives and grants.
  • Astexs development of tolinapant is aimed at bringing a new therapeutic option for patients with this type of cancer.
  • Tolinapant is a novel, orally administered, non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP).